Wanbury Limited AI Stock Analysis
Want to see IN:WANBURY full AI Analyst Report?
Wanbury Limited (WANBURY) AI Stock Analysis
Wanbury Limited
(NSE:WANBURY)
The score is constrained primarily by weak financial quality (poor cash generation and high leverage despite improved reported profitability) and bearish technical momentum (below major moving averages with negative MACD). A relatively modest P/E provides some valuation support but is not enough to offset the cash-flow and trend risks.
Wanbury Limited (WANBURY) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 6.76B
- Dividend Yield
- ―
- Average Volume (3M)
- 18.17K
- Price to Earnings (P/E)
- 12.7
- Beta (1Y)
- 1.50
- Revenue Growth
- 7.45%
- EPS Growth
- -6.56%
- Country
- India
- Employees
- 1,200
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Wanbury Limited Business Overview & Revenue Model
Company Description
Wanbury Limited is an Indian pharmaceutical company engaged in the development, manufacturing, and commercialization of both finished drug products (formulations) and active pharmaceutical ingredients (APIs). The company's diverse range of formulatio...
Wanbury Limited Financial Statement Overview
Summary
Turnaround in profitability and steady revenue expansion support the score, but it is heavily offset by very weak cash conversion (minimal operating cash flow and deeply negative free cash flow in FY2025–FY2026) and still-elevated leverage (debt greater than equity in FY2026). Margin volatility and recent gross margin compression also add sustainability risk.
Income Statement
66PositiveBalance Sheet
50NeutralCash Flow
24Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Jun 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.76B | 6.50B | 6.00B | 5.74B | 4.98B | 5.11B |
| Gross Profit | 2.71B | 2.40B | 3.05B | 2.65B | 1.89B | 2.04B |
| EBITDA | 923.32M | 1.04B | 798.13M | 985.49M | 234.91M | 1.13B |
| Net Income | 498.37M | 661.35M | 305.30M | 559.56M | -103.96M | 814.74M |
Balance Sheet | ||||||
| Total Assets | 5.72B | 5.18B | 4.14B | 3.43B | 3.04B | 3.53B |
| Cash, Cash Equivalents and Short-Term Investments | 103.00M | 76.32M | 150.63M | 34.00M | 14.94M | 226.56M |
| Total Debt | 2.37B | 2.24B | 1.77B | 1.16B | 1.09B | 1.08B |
| Total Liabilities | 4.15B | 3.73B | 3.55B | 3.16B | 3.36B | 3.76B |
| Stockholders Equity | 1.57B | 1.44B | 592.72M | 279.41M | -61.54M | -234.20M |
Cash Flow | ||||||
| Free Cash Flow | 0 | -568.35M | -229.26M | -134.45M | 71.69M | 308.65M |
| Operating Cash Flow | 0 | 27.76M | 261.02M | 39.78M | 197.97M | 405.23M |
| Investing Cash Flow | 0 | -571.12M | -511.74M | -166.25M | -88.38M | 5.87M |
| Financing Cash Flow | 0 | 518.87M | 257.33M | 145.53M | -319.91M | -285.85M |
Wanbury Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:WANBURY, the sentiment is Negative. The current price of 193.65 is above the 20-day moving average (MA) of 188.24, below the 50-day MA of 207.86, and below the 200-day MA of 249.34, indicating a neutral trend. The MACD of -2.09 indicates Negative momentum. The RSI at 47.77 is Neutral, neither overbought nor oversold. The STOCH value of 59.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:WANBURY.
Wanbury Limited Peers Comparison
Overall Rating
IN:JAGSNPHARM78Outperform
IN:LINCOLN67Neutral
IN:KILITCH63Neutral
IN:ANUHPHR61Neutral
IN:ZIMLAB60Neutral
IN:WANBURY49Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 78Outperform | INR 14.27B | 31.90 | ― | 1.84% | 11.71% | -26.92% | |
| 67Neutral | INR 10.46B | 10.87 | ― | 0.35% | 14.25% | 21.11% | |
| 63Neutral | INR 7.53B | 30.88 | ― | ― | 13.87% | -17.80% | |
| 61Neutral | INR 8.27B | 17.30 | ― | 1.82% | 6.62% | 53.57% | |
| 60Neutral | INR 7.60B | 263.30 | ― | ― | 13.14% | -60.77% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 49Neutral | INR 6.77B | 12.69 | ― | ― | 7.45% | -6.56% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:WANBURY | Wanbury Limited | 193.65 | -39.25 | -16.85% | |
| IN:JAGSNPHARM | Jagsonpal Pharmaceuticals Ltd. | 216.05 | 8.04 | 3.86% | |
| IN:KILITCH | Kilitch Drugs (India) Limited | 215.40 | 37.83 | 21.30% | |
| IN:LINCOLN | Lincoln Pharmaceuticals Ltd | 522.00 | -8.10 | -1.53% | |
| IN:ZIMLAB | Zim Laboratories Ltd. | 141.70 | 67.79 | 91.72% | |
| IN:ANUHPHR | Anuh Pharma Limited | 82.52 | 3.43 | 4.34% |
Wanbury Limited Corporate Events
Wanbury Confirms SEBI-Compliant Dematerialisation for September Quarter
Wanbury Limited has reported that it has obtained a statutory confirmation from its registrar and share transfer agent Purva Sharegistry (India) Pvt. Ltd. under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the qu...
Wanbury Gains USFDA DMF Clearance for Metformin API, Bolstering Global Expansion
Wanbury Limited announced that it has received a “No DMF deficiency” communication from the U.S. Food and Drug Administration for multiple ANDAs that use its Metformin HCl API in different formulations, indicating full compliance of its DMF filings....
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 01, 2026
